StockDuty ← Dashboard Nov 04, 2026 11:02 PM ET
SignalCorporate

Tenaya Therapeutics GAAP EPS of -$0.08 beats by $0.02, revenue of $1.7M beats by $0.9M

Tenaya's EPS and revenue both beat estimates, driven by $1.7M revenue exceeding by $0.9M.

What changed
Tenaya's EPS and revenue both beat estimates, driven by $1.7M revenue exceeding by $0.9M.
Why it matters
Tenaya's EPS and revenue both beat estimates, driven by $1.7M revenue exceeding by $0.9M. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →$FMX →